As of Aug 22
| +0.15 / +4.35%|
The 3 analysts offering 12-month price forecasts for Cancer Genetics Inc have a median target of 6.00, with a high estimate of 11.00 and a low estimate of 6.00. The median estimate represents a +66.67% increase from the last price of 3.60.
The current consensus among 3 polled investment analysts is to Buy stock in Cancer Genetics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.